UY39579A - COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS - Google Patents
COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGASInfo
- Publication number
- UY39579A UY39579A UY0001039579A UY39579A UY39579A UY 39579 A UY39579 A UY 39579A UY 0001039579 A UY0001039579 A UY 0001039579A UY 39579 A UY39579 A UY 39579A UY 39579 A UY39579 A UY 39579A
- Authority
- UY
- Uruguay
- Prior art keywords
- cgas
- compounds
- treatment
- composition
- conditions associated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 title 1
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente revelación se refiere a un compuesto de Formula (I): o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo, donde R1 hasta R8 inclusive son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128949P | 2020-12-22 | 2020-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39579A true UY39579A (es) | 2022-07-29 |
Family
ID=79164465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039579A UY39579A (es) | 2020-12-22 | 2021-12-20 | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230085472A1 (es) |
| EP (1) | EP4267564A1 (es) |
| JP (1) | JP2024502258A (es) |
| KR (1) | KR20230124665A (es) |
| CN (1) | CN116635382A (es) |
| AR (1) | AR124443A1 (es) |
| AU (1) | AU2021404953A1 (es) |
| CA (1) | CA3202212A1 (es) |
| CL (1) | CL2023001859A1 (es) |
| CO (1) | CO2023007954A2 (es) |
| CR (1) | CR20230282A (es) |
| DO (1) | DOP2023000129A (es) |
| EC (1) | ECSP23045506A (es) |
| IL (1) | IL303913A (es) |
| MX (1) | MX2023007467A (es) |
| PE (1) | PE20240229A1 (es) |
| TW (1) | TW202241873A (es) |
| UY (1) | UY39579A (es) |
| WO (1) | WO2022137085A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230391786A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | cGAS INHIBITORS |
| WO2024083773A1 (en) | 2022-10-18 | 2024-04-25 | Glaxosmithkline Intellectual Property Development Limited | Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065860A1 (es) * | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
| EP3237419B1 (en) | 2014-12-22 | 2021-02-17 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| EP3749293B1 (en) * | 2018-02-05 | 2022-03-30 | The Rockefeller University | 2,3,4,5-tetrahydro-1h-pyrido[4, 3-b]indole inhibitors of cgas for treating autoinflammatory diseases |
-
2021
- 2021-12-20 IL IL303913A patent/IL303913A/en unknown
- 2021-12-20 CR CR20230282A patent/CR20230282A/es unknown
- 2021-12-20 KR KR1020237024854A patent/KR20230124665A/ko unknown
- 2021-12-20 WO PCT/IB2021/062029 patent/WO2022137085A1/en active Application Filing
- 2021-12-20 CN CN202180079723.3A patent/CN116635382A/zh active Pending
- 2021-12-20 JP JP2023537694A patent/JP2024502258A/ja active Pending
- 2021-12-20 AR ARP210103590A patent/AR124443A1/es unknown
- 2021-12-20 TW TW110147655A patent/TW202241873A/zh unknown
- 2021-12-20 CA CA3202212A patent/CA3202212A1/en active Pending
- 2021-12-20 AU AU2021404953A patent/AU2021404953A1/en active Pending
- 2021-12-20 US US17/645,071 patent/US20230085472A1/en active Pending
- 2021-12-20 EP EP21834940.5A patent/EP4267564A1/en active Pending
- 2021-12-20 UY UY0001039579A patent/UY39579A/es unknown
- 2021-12-20 MX MX2023007467A patent/MX2023007467A/es unknown
- 2021-12-20 PE PE2023001937A patent/PE20240229A1/es unknown
-
2023
- 2023-06-20 CL CL2023001859A patent/CL2023001859A1/es unknown
- 2023-06-20 CO CONC2023/0007954A patent/CO2023007954A2/es unknown
- 2023-06-20 EC ECSENADI202345506A patent/ECSP23045506A/es unknown
- 2023-06-21 DO DO2023000129A patent/DOP2023000129A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230085472A1 (en) | 2023-03-16 |
| CL2023001859A1 (es) | 2024-02-09 |
| DOP2023000129A (es) | 2023-07-16 |
| EP4267564A1 (en) | 2023-11-01 |
| MX2023007467A (es) | 2023-07-04 |
| CR20230282A (es) | 2023-07-12 |
| AU2021404953A1 (en) | 2023-06-22 |
| PE20240229A1 (es) | 2024-02-16 |
| AR124443A1 (es) | 2023-03-29 |
| CN116635382A (zh) | 2023-08-22 |
| ECSP23045506A (es) | 2023-07-31 |
| KR20230124665A (ko) | 2023-08-25 |
| JP2024502258A (ja) | 2024-01-18 |
| WO2022137085A1 (en) | 2022-06-30 |
| IL303913A (en) | 2023-08-01 |
| CO2023007954A2 (es) | 2023-06-30 |
| AU2021404953A9 (en) | 2024-02-08 |
| CA3202212A1 (en) | 2022-06-30 |
| TW202241873A (zh) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| UY39579A (es) | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS | |
| CU20190086A7 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats | |
| UY38057A (es) | Inhibidores de sarcómero cardíaco | |
| CR20110059A (es) | Compuestos organicos | |
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| CO2020006523A2 (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| ECSP21016009A (es) | Inhibidores de sarcómeros cardíacos | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| AR116116A1 (es) | Proceso para elaborar inhibidores de jak e intermediarios de los mismos | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| CO2018007663A2 (es) | Compuestos indolinonas y su uso en el tratamiento de enfermedades fibróticas | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| UY38618A (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos | |
| UY36074A (es) | ?derivados de dihidropirrolopirimidina? . | |
| CL2021000729A1 (es) | Derivados de indano para el uso en el tratamiento de infección bacteriana | |
| PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |